Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a “tobacco substitute”
In Switzerland, only cannabis with a total Δ9-tetrahydrocannabinol (THC) content higher than 1% is controlled by the narcotics legislation. Cannabis products rich in cannabidiol (CBD) and low in THC can be legally sold as tobacco substitutes. In this paper, we address analytical and forensic toxicological issues related to the increasing availability and consumption of these products. Based on the analysis of 531 confiscated cannabis samples, we could establish classification thresholds: plant material with a ratio of total THC/total CBD ≥ 3 is graded as THC-rich/CBD-poor, whereas samples with a ratio ≤ 0.33 are categorized as CBD-rich/THC-poor cannabis. We also evaluated an on-site test kit as a rapid alternative to the laborious liquid or gas chromatography (LC or GC)-based techniques normally used for the differentiation between THC- and CBD-cannabis. Furthermore, we determined whole blood and urine cannabinoid levels after smoking different doses of legal CBD-cannabis. A male volunteer smoked one cigarette within 15 min and four cigarettes within 1 h and within 30 min, respectively. Cigarettes contained on average 42.7 mg CBD and 2.2 mg THC. Blood samples were collected up to 1.1 h and urine samples up to 27.3 h after the beginning of smoking. All urine samples tested negative by three immunochemical assays for detection of cannabis use. This is an important finding for abstinence monitoring. However, we found that the trace amounts of THC present in CBD-cannabis can produce THC blood levels above the Swiss legal limit for driving, and thus render the consumer unable to drive from a legal point of view.
KeywordsTetrahydrocannabinol Cannabidiol Classification Drug of abuse testing Driving while impaired
The authors gratefully acknowledge Alain Broillet, Beatrice Grossen, and Severine Krönert for the evaluation of the on-site test kit and the analyses of confiscated cannabis samples, Thomas Wüthrich for his support with LC-MS/MS data acquisition and the whole team of the Forensic Toxicology laboratory at the Institute of Forensic Medicine Bern for supporting this project.
Compliance with ethical standards
According to the ethics committee of the Canton of Bern, Switzerland, this study does not apply to Art. 3a of the Federal Act on Research involving Human Beings (Human Research Act) since it is a study only involving one participant—who was the principal investigator himself in a self-experiment. Therefore, they did not decide on the application listed with the project ID No. 2018-01037. However, written informed consent was obtained from the participant of the cannabis smoking study.
All procedures performed were in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Clarke RC, Merlin MD (2013) Cannabis - evolution and ethnobotany. University of California PressGoogle Scholar
- 4.Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, Slater M, Godlewska B, Cornish R, Williams J, Di Simplicio M, Igoumenou A, Brenneisen R, Tunbridge EM, Harrison PJ, Harmer CJ, Cowen P, Morrison PD (2015) How cannabis causes paranoia: using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull 41(2):391–399. https://doi.org/10.1093/schbul/sbu098 CrossRefGoogle Scholar
- 9.Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041 CrossRefGoogle Scholar
- 13.Swiss_Ordinance_on_the_lists_of_narcotics ps, _precursors_and_auxiliary_chemicals. https://www.admin.ch/opc/de/classified-compilation/20101220/index.html. Accessed Jul 21 2017
- 15.Schläpfer M (2018) Cannabis Typisierung - differenzierung auf der Strasse. Kriminalistik - Schweiz 4:258–261Google Scholar
- 16.Verstraete AG, Knoche A, Jantos R, Skopp G, Gjerde H, Vindenes V, Mørland J, Langel K, Lillsunde P (2011) Per se limits - methods of defining cut-off values for zero tolerance. https://biblio.ugent.be/publication/1988464/file/1988490.pdf. Accessed 12 Dec 2018
- 19.Tsai J (2007) Immunoassays for the detection of cannabis abuse: technologies, development strategies, and multilevel applications. In: ElSohly M (ed) Marijuana and the cannabinoids. Human Press Inc., TotowaGoogle Scholar
- 20.R_Core_Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
- 21.König S, Aebi B, Lanz S, Gasser M, Weinmann W (2011) On-line SPE LC-MS/MS for the quantification of Delta9-tetrahydrocannabinol (THC) and its two major metabolites in human peripheral blood by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 400(1):9–16. https://doi.org/10.1007/s00216-011-4708-x CrossRefGoogle Scholar
- 24.SGRM (2017) THC Statistik 2017. https://www.sgrm.ch/inhalte/Forensische-Chemie-und-Toxikologie/THC_Statistik_SGRM_2017.pdf. Accessed Sep 07 2018
- 25.Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannibinol, cannabidiol and cannabinol. Handb Exp Pharmacol 168. https://doi.org/10.1007/3-540-26573-2-23
- 34.Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38(1):21–43Google Scholar
- 35.Schwope DM, Karschner EL, Gorelick DA, Huestis MA (2011) Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 57(10):1406–1414. https://doi.org/10.1373/clinchem.2011.171777 CrossRefGoogle Scholar
- 37.Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, Fornari E, Lauer E, Maeder P, Giroud C (2013) Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Anal Bioanal Chem 405(30):9791–9803. https://doi.org/10.1007/s00216-013-7412-1 CrossRefGoogle Scholar
- 39.Giroud C, Menetrey A, Augsburger M, Buclin T, Sanchez-Mazas P, Mangin P (2001) Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int 123(2–3):159–164CrossRefGoogle Scholar